| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.10. | Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal | ||
| 20.10. | Rapport's epilepsy drug finds surprising success in bipolar trial | ||
| 20.10. | Most new drugs are still too costly at launch, ICER says | ||
| 20.10. | Hype vs. reality: What pharma's hottest R&D bets have actually proved | ||
| 19.10. | Disc's once-spurned rare disease drug to get a second chance at approval | ||
| 19.10. | Merck KGaA bets on RNAi with $1.3B Silence buyout | ||
| 19.10. | Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study | ||
| 19.10. | From strategy to scale: How Saudi Arabia is building a biotech ecosystem | ||
| 19.10. | Extractables in single-use systems used in ADC manufacturing | ||
| 19.10. | How early should you engage a CDMO? | ||
| 16.10. | Iambic CEO on taking an AI drug company public | ||
| 16.10. | This week in charts: Moderna's massive stock run | ||
| 16.10. | Next-gen RNAi drugmaker City prices $200M IPO | ||
| 16.10. | Biogen-backed Estuary nabs $93M for liver disease gene therapy | ||
| 15.10. | Belgian startup revives Galapagos CAR-T research | ||
| 15.10. | FDA 'reset' continues with new plan for reviewing rare disease drugs | ||
| 15.10. | Iambic, an AI drug discovery specialist, banks $150M in an IPO | ||
| 14.10. | Experimental Arrowhead RNAi drug hints at Alzheimer's benefit | ||
| 14.10. | J&J earnings set 'negative tone'; Shkreli vs. the FTC | ||
| 14.10. | Verastem cancer drug shows early promise in small study | ||
| 13.10. | Decreasing process variability in fluid management systems | ||
| 13.10. | Another Paragon Labs spinout goes public through reverse merger | ||
| 13.10. | BioNTech mRNA cancer immunotherapy misses first objective in key study | ||
| 13.10. | Roche extends China deal streak with $1B pact for RNAi obesity drug | ||
| 12.10. | First Tracks climbs on 'impressive' celiac study data |